initial public offerings (IPOs) trading on American exchanges

Monday, August 19, 2013

Heat Biologics (HTBX) began trading on the NASDAQ on 24 July 2013


Heat Biologics is a development-stage biopharmaceutical company engaged in the development of allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. Its ImmunePan Antigen Cytotoxic Therapy (ImPACT) is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to pump out a range of cancer-associated antigens together with a immune adjuvant called gp96 to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Its primary product candidates are HS-110 and HS-410. It is also developing ImPACT therapeutic vaccines for breast cancer and ovarian cancer.


Suite 420, 100 Europa Drive
United States

Website links

Key stats and ratios

Q1 (Mar '13)2012
Net profit margin--3483.60%
Operating margin-0.00%
EBITD margin-83.28%
Return on average assets-2.71%-65.73%
Return on average equity-1409.31%-

No comments:

Post a Comment